CYP2C9 Inhibitor Screening Kit (F), Catalog: MA-0392

Catalog MA-0392

Size 100 wells

Sample Type Samples Containing Drugs, Inhibitors or Ligands (compounds that can interact and affect CYP2C9 activity)

Method of Detection Fluorometric, Ex/Em = 415/502 nm

Assay Type Quantitative

Application A simple, sensitive sensitive way to evaluate drug and chemical interactions with CYP2C9.

Storage Conditions -20°C

Shipping Temperature Gel Pack

Shelf Life One year from the date of delivery

The cytochrome P450’s are a monooxygenase superfamily which includes over 17,000 genes, including 57 in humans. CYP2C9  is unique due to its high genetic variability and resulting inter-individual differences in drug metabolism, particularly for warfarin and other narrow therapeutic index drugs. This often leads to significant variability in patient response and potential for adverse drug reactions. Localized primarily in the liver, it is responsible for metabolizing ~20% of commonly used drugs and is significantly influenced by genetic polymorphisms. AkrivisBio’s CYP2C9 Inhibitor Screening Kit is a simple, sensitive way to evaluate drug and chemical interactions with CYP2C9.